High-dose CBD reduces THC absorption when both are inhaled together

When CBD and THC were co-administered by vaporization, high-dose CBD significantly decreased the systemic availability of THC, with frequent cannabis users showing higher availability of both compounds.

Liu, Zheng et al.·Internal medicine journal·2020·Moderate EvidenceRandomized Controlled Trial
RTHC-02690Randomized Controlled TrialModerate Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Randomized Controlled Trial
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

In a randomized, double-blind, crossover study, concomitant inhalation of high-dose CBD significantly decreased the systemic availability of THC. Population pharmacokinetic models showed that frequent cannabis users had higher systemic availability of both THC and CBD compared to infrequent users.

Key Numbers

High-dose CBD significantly decreased THC systemic availability. Frequent users had higher availability of both compounds. Population PK models developed for both THC and CBD.

How They Did This

Randomized, double-blind, crossover, placebo-controlled design. THC and/or CBD in ethanol were vaporized and inhaled. Plasma concentrations analyzed and population pharmacokinetic models developed by pooling with published data.

Why This Research Matters

Many medical cannabis users consume both THC and CBD. Understanding how they interact pharmacokinetically is essential for dosing guidance. The finding that CBD reduces THC availability could explain why CBD-rich products feel less intoxicating.

The Bigger Picture

This finding has practical implications: adding CBD to THC products may actually reduce THC exposure, not just modulate its effects subjectively. This could inform product design and dosing recommendations for medical cannabis.

What This Study Doesn't Tell Us

Relatively small sample; vaporized administration only (results may differ for oral or sublingual routes); pooled data from different studies for PK modeling; acute dosing only.

Questions This Raises

  • ?Does the CBD-THC interaction hold for oral administration?
  • ?Should medical cannabis dosing account for CBD-mediated reduction in THC availability?

Trust & Context

Key Stat:
High-dose CBD significantly decreased THC systemic availability when co-inhaled
Evidence Grade:
Moderate: randomized, double-blind crossover design with PK modeling, though sample size was limited.
Study Age:
Published 2020.
Original Title:
Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
Published In:
Internal medicine journal, 50(7), 846-853 (2020)
Database ID:
RTHC-02690

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled TrialGold standard for testing treatments
This study
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Participants are randomly assigned to treatment or placebo groups to test cause and effect.

What do these levels mean? →

Frequently Asked Questions

Does CBD reduce the effects of THC?

This study found that co-inhaling high-dose CBD reduced the amount of THC that reaches the bloodstream. This pharmacokinetic interaction could contribute to why CBD-rich products feel less intoxicating.

Do frequent cannabis users absorb more THC?

Yes. Frequent users had higher systemic availability of both THC and CBD compared to infrequent users, possibly due to differences in inhalation technique or metabolic adaptation.

Read More on RethinkTHC

Cite This Study

RTHC-02690·https://rethinkthc.com/research/RTHC-02690

APA

Liu, Zheng; Galettis, Peter; Broyd, Samantha J; van Hell, Hendrika; Greenwood, Lisa-Marie; de Krey, Peter; Steigler, Amy; Zhu, Xiao; Schneider, Jennifer; Solowij, Nadia; Martin, Jennifer H. (2020). Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.. Internal medicine journal, 50(7), 846-853. https://doi.org/10.1111/imj.14415

MLA

Liu, Zheng, et al. "Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.." Internal medicine journal, 2020. https://doi.org/10.1111/imj.14415

RethinkTHC

RethinkTHC Research Database. "Model-based analysis on systemic availability of co-administ..." RTHC-02690. Retrieved from https://rethinkthc.com/research/liu-2020-modelbased-analysis-on-systemic

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.